Risk factors for major adverse cardiovascular events after the first acute coronary syndrome

Ann Med. 2021 Dec;53(1):817-823. doi: 10.1080/07853890.2021.1924395.

Abstract

Aims: To evaluate risk factors for major adverse cardiac event (MACE) after the first acute coronary syndrome (ACS) and to examine the prevalence of risk factors in post-ACS patients.

Methods: We used Finnish population-based myocardial infarction register, FINAMI, data from years 1993-2011 to identify survivors of first ACS (n = 12686), who were then followed up for recurrent events and all-cause mortality for three years. Finnish FINRISK risk factor surveys were used to determine the prevalence of risk factors (smoking, hyperlipidaemia, diabetes and blood pressure) in post-ACS patients (n = 199).

Results: Of the first ACS survivors, 48.4% had MACE within three years of their primary event, 17.0% were fatal. Diabetes (p = 4.4 × 10-7), heart failure (HF) during the first ACS attack hospitalization (p = 6.8 × 10-15), higher Charlson index (p = 1.56 × 10-19) and older age (p = .026) were associated with elevated risk for MACE in the three-year follow-up, and revascularization (p = .0036) was associated with reduced risk. Risk factor analyses showed that 23% of ACS survivors continued smoking and cholesterol levels were still high (>5mmol/l) in 24% although 86% of the patients were taking lipid lowering medication.

Conclusion: Diabetes, higher Charlson index and HF are the most important risk factors of MACE after the first ACS. Cardiovascular risk factor levels were still high among survivors of first ACS.

Keywords: Epidemiology; acute coronary syndromes; major adverse cardiac event; prevention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome* / epidemiology
  • Acute Coronary Syndrome* / etiology
  • Aged
  • Diabetes Mellitus* / epidemiology
  • Heart Failure* / epidemiology
  • Heart Failure* / etiology
  • Humans
  • Myocardial Infarction* / epidemiology
  • Myocardial Infarction* / etiology
  • Risk Assessment
  • Risk Factors

Grants and funding

FINAMI study was supported by the Finnish Foundation for Cardiovascular Research. MO has received funding from the Medical Research Centre of Oulu Doctoral Program and State Research Funding. VS has received funding from the Finnish Foundation for Cardiovascular Research.